76 related articles for article (PubMed ID: 741221)
1. Schedule dependency of anticancer effect of 1-beta-D-arabinofuranosylcytosine on rat ascites hepatomas.
Abe I; Sato S; Watanabe M; Sato H
Sci Rep Res Inst Tohoku Univ Med; 1978 Sep; 25(1-2):20-3. PubMed ID: 741221
[No Abstract] [Full Text] [Related]
2. Mechanism of natural resistance of rat ascites hepatomas to 1-beta-D-arabinofuranosylcytosine.
Abe I; Sato S; Watanabe M; Sato H
Gan; 1978 Aug; 69(4):557-64. PubMed ID: 710805
[TBL] [Abstract][Full Text] [Related]
3. Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro.
Shackney SE; Ford SS; Occhipinti SJ; Ritch PS; Riccardi R; Erickson BW
Cancer Res; 1982 Nov; 42(11):4339-47. PubMed ID: 7127279
[No Abstract] [Full Text] [Related]
4. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Schwartz SA; Morgenstern B; Capizzi RL
Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
[TBL] [Abstract][Full Text] [Related]
5. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.
Kim S; Kim DJ; Geyer MA; Howell SB
Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine.
Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi J; Ishida T
Cancer Res; 1976 Aug; 36(8):2726-32. PubMed ID: 1277182
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
[No Abstract] [Full Text] [Related]
8. New antitumor amino acid derivative, A-748, evaluated in rat ascites hepatomas.
Fujita H; Sakurai T; Toyoshima S
Cancer Treat Rep; 1979 Feb; 63(2):223-4. PubMed ID: 445498
[No Abstract] [Full Text] [Related]
9. mRNA levels and enzyme activities of protein phosphatases in drug-resistant rat ascites hepatomas.
Saadat M; Saeki H; Kudo T; Mizuno Y; Kikuchi K
Oncol Res; 1995; 7(10-11):505-10. PubMed ID: 8866662
[TBL] [Abstract][Full Text] [Related]
10. Effect of thymidine on the toxicity, antitumor activity, and metabolism of 1-beta-D-arabinofuranosylcytosine in rats bearing a chemically induced colon carcinoma.
Danhauser LL; Rustum YM
Cancer Res; 1980 Apr; 40(4):1274-80. PubMed ID: 7357557
[No Abstract] [Full Text] [Related]
11. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Vaughan WP; Burke PJ
Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
[TBL] [Abstract][Full Text] [Related]
12. Drug induced host factors which stimulate growth of residual leukemia in Lewis x Brown Norway F1 (LEW-BN) rats.
Burke PJ; Karp JE; Saylor PL
Cancer Res; 1986 Apr; 46(4 Pt 1):1813-6. PubMed ID: 3485014
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.
Berdel WE; Okamoto S; Danhauser-Riedl S; Hong CI; Winton EF; West CR; Rastetter J; Vogler WR
Exp Hematol; 1989 May; 17(4):364-7. PubMed ID: 2707318
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma].
Satoh H; Taguchi H; Yahagi S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):287-91. PubMed ID: 2137321
[TBL] [Abstract][Full Text] [Related]
15. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
[TBL] [Abstract][Full Text] [Related]
16. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
17. Cell population size dependency of therapeutic effect of divided dosage of 1-beta-D-arabinofuranosylcytosine.
Abe I; Sato S
Gan; 1976 Jun; 67(3):461-4. PubMed ID: 1001871
[TBL] [Abstract][Full Text] [Related]
18. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi JI; Ishida T
Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
20. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia.
Barlogie B; Plunkett W; Raber M; Latreille J; Keating M; McCredie K
Cancer Res; 1981 Mar; 41(3):1227-35. PubMed ID: 7459863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
